Company: NCEL
Filing Date: 2025-06-06
Form Type: 6-K
Source: 0001213900-25-052094
Chunk: 3

Company: NewcelX Ltd.
Filing Date: 2025-06-06
Form: 6-K
Chunk 3
---
 important information about the Company and the proposed transaction, once such documents are filed with the SEC through the website maintained by the SEC at http://www.sec.gov. Copies of the documents filed with the SEC by the Company will be available free of charge on the Company’s website at www.nlspharma.com.

Participants in the Solicitation

The
Company and certain of its respective directors and executive officers may be deemed to be participants in the solicitation of proxies
from the Company’s shareholders in respect of the proposed transaction. Information about the directors and executive officers of
the Company, including a description of their direct or indirect interests, by security holdings or otherwise, is set forth in the Company’s
Annual Report on Form 20-F for the fiscal year ended December 31, 2024, which was filed with the SEC on May 16, 2025. Other information
regarding the participants in the proxy solicitation and a description of their direct and indirect interests, by security holdings or
otherwise, are contained in the F-4 Registration Statement and other relevant materials to be filed with the SEC regarding the proposed
transaction when such materials become available. Investors should read the proxy statement/prospectus carefully when it becomes available
before making any voting or investment decisions. You may obtain free copies of these documents from the Company using the sources indicated
above.

<div align='center'>EXHIBIT INDEX</div>

<div align='center'>2

SIGNATURES</div>

Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.

| Date: June 6, 2025 | NLS Pharmaceutics Ltd. 
 By:                    | /s/             
 Alexander Zwyer |                         |
|:-------------------|:-----------------------|:----------------|:------------------------|
|                    |                        | Name:           | Alexander Zwyer         |
|                    |                        | Title:          | Chief Executive Officer |

<div align='center'>3</div>